December 2023 Quarterly Activities Report & Appendix 4C
Released
Released
Announcement PDF
ASX Announcement
31 January 2024
Avecho Quarterly Activities Report and Appendix 4C
Melbourne, Australia, 31 January 2024: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the
“Company”) is pleased to release its Quarterly Activities Report and Appendix 4C for the quarter ended 31
December 2023.
During the quarter, the Company focused on preparations for the pivotal Phase III trial of its proprietary
CBD soft gel capsule targeting insomnia, due to commence late Q1 2024. Being the key pillar for Avecho
entering the 2024 calendar year, the strategy, planning and opportunity for its CBD soft gel capsule
technology is summarised as follows.
PHASE III STUDY DESIGN
Avecho's Phase III trial for its proprietary CBD soft gel capsule has been carefully planned using both the
pharmaceutical industry experience of management, global key opinion leaders in the field of sleep medicine
and learnings from other insomnia trials conducted around the world.
Participants who meet the required conditions for enrolment will be divided into three treatment groups:
-
One receiving a placebo
One receiving a 75 mg dosage of the CBD capsule
One receiving a 150mg dosage of the CBD capsule
This randomized, placebo-controlled setup is vital for the trial's credibility and accuracy. Spanning eight
weeks, the study diligently monitors patient progress using daily sleep diaries and questionnaires.
It will be conducted across five major cities in Australia, involving 519 participants, thus ensuring a substantial
sample size for reliable results.
This large-scale approach, combined with the varied dosage and the rigorous monitoring, is indicative of
Avecho's commitment to demonstrating the effectiveness of CBD in treating insomnia. The study's outcomes
could significantly contribute to the field of sleep medicine, as insomnia remains a large problem affecting a
significant percentage of the population.
TIMELINES TO INTERIM ANALYSIS – A MAJOR CATALYST
The interim analysis in Avecho's Phase III study represents a critical inflection point. Scheduled late calendar
2024, this analysis will evaluate sleep improvements in the three different groups without revealing group
identities to the statisticians. This blind assessment is crucial for maintaining objectivity.
Based on the difference in sleep scores recorded for the three treatment groups, statisticians will conduct a
formal powering calculation to determine how many more participants are needed to maximise the chance
of statistical significance. This adaptive aspect of the study allows for necessary adjustments based on realtime data, maximising the study's potential for success.
If no significant difference in sleep quality is found among the groups, the Company will have the opportunity
to halt the study early in order to preserve capital.
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
The interim analysis, which was not used in previous Phase III CBD trials, is a critical component of Avecho’s
study that will maximise the chance of a successful outcome in real time, which protecting the Company
from additional expenditure if the results do not look positive.
THE DANGER OF THE PLACEBO RESPONSE
In clinical trials, especially in studies focusing on subjective outcomes like sleep quality, the placebo response
is a noteworthy challenge. This phenomenon, where patients report improvements after receiving a nonactive treatment, can blur the actual effectiveness of the drug under study. In the context of insomnia, where
self-assessment is key in gauging treatment success, this issue is particularly pertinent.
Avecho's trial design incorporates specific strategies to mitigate the placebo effect. This precaution underlines
the company's proactive approach in ensuring the accuracy and reliability of its study results. Addressing the
placebo response head-on is critical for interpreting a drug's true efficacy and can influence patient care and
future drug development strategies.
THE OPPORTUNITY FOR AVECHO
Avecho's Phase III study occurs at a pivotal moment, particularly considering Australia's unique regulatory
environment that allows OTC registration of pharmaceutical CBD products. This situation presents a
significant commercial opportunity, as OTC products can be accessible directly to consumers without
prescriptions. With insomnia being a widespread problem and existing treatments having various limitations,
Avecho's market entry could fulfill a substantial unmet medical need.
The Company’s strategic focus on insomnia leverages the prevalent condition to explore a potentially lucrative
market segment. The potential approval of Avecho's CBD product for insomnia by the TGA could set it apart
in this emerging market. This not only addresses a major health concern but also positions Avecho to
capitalise on the growing demand for alternative, effective sleep aids.
The combination of market dynamics and the regulatory landscape in Australia creates a large opportunity
for Avecho in the pharmaceutical CBD sector where other businesses have been unable to succeed.
US BUSINESS DEVELOPMENT
During the quarter, Avecho’s CEO dedicated a substantial amount of time to exploring business opportunities
within the North America medicinal and recreational cannabis market.
Having developed at an earlier time and with varied dynamics compared with Australia, North America
presents unique opportunities for Avecho’s technologies. Recognising the dynamic landscape and evolving
regulatory environment, Dr Gavin sought to position the Company as a technology leader with various
industry experts and potential business partners in the region.
Dr Gavin also travelled to San Francisco for the recent JP Morgan Healthcare week which brings together a
range of the leading biotechnology and pharmaceutical groups from around the world.
The meetings and interactions from these business development activities provided a platform to showcase
Avecho's expertise, discuss potential collaborations, and explore avenues for strategic partnerships. The
Company will update the market as to future material developments arising from these discussions.
2
CORPORATE
During the quarter ended 31 December 2023, the Company received a sum of ~A$2.4 million, net of
transaction fees, from the Tranche 2 Placement capital raise.
The Company held a General Meeting on 9 November 2023 to seek shareholder approval on corporate
transactions related to the Placement:
a)
The Placement raised ~A$6 million before costs in two tranches:
~A$3.2million raised through the issue of ~536 million of fully paid ordinary shares (“AVE
Shares”) at $0.006 each to professional and sophisticated investors on 8 September 2023; and
~A$2.8 million raised through the issue of ~471 million AVE Shares to professional and
sophisticated investors (including to directors Mr Matthew Patrick McNamara and Dr Gregory
Collier) at $0.006 each on 22 November 2023 following shareholder approval on 9 November
2023. 1,666,666 and 5,833,333 AVE Shares were respectively issued to Mr McNamara and Dr
Collier.
b) Quoted Options:
~1,499 million quoted Options exercisable at $0.012 (1.2 cents) each and expiring on 10 May
2026 were issued on 22 November 2023 to professional and sophisticated investors who
participated to the Placement following receipt of shareholder approval.
150 million quoted Options exercisable at $0.012 (1.2 cents) each and expiring on 10 May 2026
were also issued on 22 November 2023 (“Broker Options”). The purpose of the issue of Broker
Options to the Joint Lead Managers was for fees payable to them as joint lead managers for
services.
The Company also had 122,443,182 quoted Options exercisable at $0.035 each which expired on 31
December 2023 without being exercised.
In addition, during the quarter the Company invested ~A$878K in R&D activities and incurred administration
and corporate costs of ~A$660K. Administration and corporate costs during the quarter were higher
compared to historical amounts due to investor relationships, capital raising fees and insurance renewals. At
the end of the quarter, the Company held ~A$5.5 million in cash.
Payments to related parties and their associates during the quarter, as outlined in Section 6 of the
accompanying Appendix 4C to these quarterly activities report, were ~A$53K.
For enquiries, please contact
Dr Paul Gavin
Chief Executive Officer
Avecho Biotechnology Limited
+61 3 9002 5000
This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.
About Avecho
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products
using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived
from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and
oral, dermal and transdermal absorption of drugs and nutrients.
Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the
human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.
See more here - avecho.com.au
3
Forward-Looking Statements
Certain statements in this announcement are forward looking statements. Forward looking statements can
generally be identified by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “intend”,
“plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward-looking statements
speak only as at the date of this announcement. These statements are based on current expectations and
beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that
could cause the actual results, performances and achievements to differ materially from any expected future
results, performance or achievements expressed or implied by such forward looking statements.
No representation, warranty or assurance (express or implied) is given or made by AVE that the
forwardlooking statements contained in this announcement are accurate, complete, reliable or adequate or
that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded,
AVE and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy
or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence)
for any direct or indirect loss or damage which may be suffered by any person as a consequence of any
information in this announcement or any error or omission therefrom.
Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, AVE disclaims
any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in
these materials to reflect any change in expectations in relation to any forward-looking statements or any
change in events, conditions or circumstances on which any statement is based. Nothing in these materials
shall under any circumstances create an implication that there has been no change in the affairs of AVE since
the date of the announcement.
4
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
AVECHO BIOTECHNOLOGY LIMITED
ABN
Quarter ended (“current quarter”)
32 056 482 403
31 December 2023
Consolidated statement of cash flows
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Current quarter
$A’000
Year to date (9
months)
$A’000
23
758
(a) research and development
(878)
(2,313)
(b) product manufacturing and operating
costs
(92)
(212)
(c) advertising and marketing
-
-
(d) leased assets
-
-
(e) staff costs*
3
(552)
(660)
(75)
(1,568)
(295)
-
-
(f) administration and corporate costs
(g) patent portfolio costs
1.3
Dividends received (see note 3)
1.4
Interest received
24
36
1.5
Interest and other costs of finance paid
(3)
(12)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
37
724
1.8
Other (EMDG)
-
-
1.9
Net cash from / (used in) operating
activities
(1,621)
(3,434)
*A percentage of staff costs are reallocated to payments for research and development. Amounts
during the current quarter was adjusted to reflect the staff cost reallocation to payments for research
and development during 1 July to 31 December 2023.
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(h) entities
-
-
(i)
businesses
-
-
(j)
property, plant and equipment
-
-
-
-
(k) investments
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
(l)
2.2
Current quarter
$A’000
Year to date (9
months)
$A’000
intellectual property
-
-
(m) other non-current assets
-
-
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
Proceeds from disposal of:
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
-
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
2,644
8,004
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
(237)
(463)
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9(a)
Other – Payment of principal element of
lease liabilities
(19)
(71)
3.9(b)
Other – Advances for shares*
-
-
3.10
Net cash from / (used in) financing
activities
2,388
7,470
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
Current quarter
$A’000
Year to date (9
months)
$A’000
4,737
1,468
(1,621)
(3,434)
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
-
-
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
2,388
7,470
4.5
Effect of movement in exchange rates on
cash held
-
-
4.6
Cash and cash equivalents at end of
period
5,504
5,504
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
5,488
4,221
5.2
Call deposits
16
516
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
5,504
4,737
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
(53)
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Current quarter
$A'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
-
N/A
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(1,621)
8.2
Cash and cash equivalents at quarter end (item 4.6)
5,504
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
5,504
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
3.39
-
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: N/A
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
31 January 2024
Authorised by: By the Board of Avecho Biotechnology Limited
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover